Endostatin's antiangiogenic signaling network

Molecular Cell

Volumn 13, Issue 5, 2004, Pages 649-663

  Abdollahi, Amir ^a   Hahnfeldt, Philip ^b   Maercker, Christian ^c   Gröne, Hermann Josef ^d   Debus, Juergen ^a   Ansorge, Wilhelm ^e   Folkman, Judah ^f   Hlatky, Lynn ^b   Huber, Peter E ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b HARVARD MEDICAL SCHOOL   (United States)

^c German Genome Resource Center RZPD   (Germany)

^d GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^e EUROPEAN MOLECULAR BIOLOGY LABORATORY   (Germany)

^f BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; ENDOSTATIN; HYPOXIA INDUCIBLE FACTOR 1ALPHA;

ANGIOGENESIS; ARTICLE; DOWN REGULATION; GENE CONTROL; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENOME; MICROVASCULATURE; PHOSPHORYLATION; PROTEIN FUNCTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIUM;

CELLS, CULTURED; DNA-BINDING PROTEINS; ENDOSTATINS; ENDOTHELIAL CELLS; EPHRINS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; INHIBITOR OF DIFFERENTIATION PROTEIN 1; NEOVASCULARIZATION, PHYSIOLOGIC; NF-KAPPA B; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-ETS; REPRESSOR PROTEINS; RNA, MESSENGER; SIGNAL TRANSDUCTION; STAT1 TRANSCRIPTION FACTOR; TRANS-ACTIVATORS; TRANSCRIPTION FACTOR AP-1; TRANSCRIPTION FACTORS; TUMOR NECROSIS FACTOR-ALPHA; UP-REGULATION;

EID: 1642307340     PISSN: 10972765     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1097-2765(04)00102-9     Document Type: Article

References (75)

1. Abdollahi A., Lipson K.E., Han X., Krempien R., Trinh T., Weber K.J., Hahnfeldt P., Hlatky L., Debus J., Howlett A.R.et al. SU5416 and SU6668 attenuate the angiogenic effects of radiation-induced tumor cell growth factor production and amplify the direct anti-endothelial action of radiation in vitro. Cancer Res. 63:2003;3755-3763. a.
2. Abdollahi A., Lipson K.E., Sckell A., Zieher H., Klenke F., Poerschke D., Roth A., Han X., Krix M., Bischof M.et al. Combined therapy with direct and indirect angiogenesis inhibition results in enhanced antiangiogenic and antitumor effects. Cancer Res. 63:2003;8890-8898. b.
3. Bargou R.C., Emmerich F., Krappmann D., Bommert K., Mapara M.Y., Arnold W., Royer H.D., Grinstein E., Greiner A., Scheidereit C.et al. Constitutive nuclear factor-kappaB-RelA activation is required for proliferation and survival of Hodgkin's disease tumor cells. J. Clin. Invest. 100:1997;2961-2969.
4. Bartoli M., Gu X., Tsai N.T., Venema R.C., Brooks S.E., Marrero M.B., Caldwell R.B. Vascular endothelial growth factor activates STAT proteins in aortic endothelial cells. J. Biol. Chem. 275:2000;33189-33192.
5. Beg A.A., Baltimore D. An essential role for NF-kappaB in preventing TNF-alpha-induced cell death. Science. 274:1996;782-784.
6. Benezra R., Davis R.L., Lockshon D., Turner D.L., Weintraub H. The protein Id. a negative regulator of helix-loop-helix DNA binding proteins Cell. 61:1990;49-59.
7. Berger A.C., Feldman A.L., Gnant M.F., Kruger E.A., Sim B.K., Hewitt S., Figg W.D., Alexander H.R., Libutti S.K. The angiogenesis inhibitor, endostatin, does not affect murine cutaneous wound healing. J. Surg. Res. 91:2000;26-31.
8. Boer J.M., Huber W.K., Sultmann H., Wilmer F., von Heydebreck A., Haas S., Korn B., Gunawan B., Vente A., Fuzesi L.et al. Identification and classification of differentially expressed genes in renal cell carcinoma by expression profiling on a global human 31,500-element cDNA array. Genome Res. 11:2001;1861-1870.
9. Bories J.C., Willerford D.M., Grevin D., Davidson L., Camus A., Martin P., Stehelin D., Alt F.W. Increased T-cell apoptosis and terminal B-cell differentiation induced by inactivation of the Ets-1 proto-oncogene. Nature. 377:1995;635-638.
10. Bowman T., Garcia R., Turkson J., Jove R. STATs in oncogenesis. Oncogene. 19:2000;2474-2488.
11. Browder T., Folkman J., Pirie-Shepherd S. The hemostatic system as a regulator of angiogenesis. J. Biol. Chem. 275:2000;1521-1524.
12. Buettner R., Mora L.B., Jove R. Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. Clin. Cancer Res. 8:2002;945-954.
13. Carmeliet P. Biomedicine. Clotting factors build blood vessels. Science. 293:2001;1602-1604.
14. Chambers R.C., Leoni P., Kaminski N., Laurent G.J., Heller R.A. Global expression profiling of fibroblast responses to transforming growth factor-beta1 reveals the induction of inhibitor of differentiation-1 and provides evidence of smooth muscle cell phenotypic switching. Am. J. Pathol. 162:2003;533-546.
15. Chang L., Karin M. Mammalian MAP kinase signalling cascades. Nature. 410:2001;37-40.
16. Cheng N., Chen J. Tumor necrosis factor-alpha induction of endothelial ephrin A1 expression is mediated by a p38. J. Biol. Chem. 276:2001;13771-13777.
17. Davis R.J. Signal transduction by the JNK group of MAP kinases. Cell. 103:2000;239-252.
18. Duhamel-Clerin E., Orvain C., Lanza F., Cazenave J.P., Klein-Soyer C. Thrombin receptor-mediated increase of two matrix metalloproteinases, MMP-1 and MMP-3, in human endothelial cells. Arterioscler. Thromb. Vasc. Biol. 17:1997;1931-1938.
19. Ferreras M., Felbor U., Lenhard T., Olsen B.R., Delaisse J. Generation and degradation of human endostatin proteins by various proteinases. FEBS Lett. 486:2000;247-251.
20. Folkman J., Kalluri R. Tumor Angiogenesis. Bast R.C. Jr., Kufe D.W., Pollock R.E.et al. Cancer Medicine. 2003;B.C. Decker, Ontario.
21. Funatsu H., Yamashita H., Noma H., Shimizu E., Yamashita T., Hori S. Stimulation and inhibition of angiogenesis in diabetic retinopathy. Jpn. J. Ophthalmol. 45:2001;577-584.
22. Ghosh S., Karin M. Missing pieces in the NF-kappaB puzzle. Cell. 109(Suppl):2002;S81-S96.
23. Hahnfeldt P., Panigrahy D., Folkman J., Hlatky L. Tumor development under angiogenic signaling. a dynamical theory of tumor growth, treatment response, and postvascular dormancy Cancer Res. 59:1999;4770-4775.
24. Hajitou A., Grignet C., Devy L., Berndt S., Blacher S., Deroanne C.F., Bajou K., Fong T., Chiang Y., Foidart J.M.et al. The antitumoral effect of endostatin and angiostatin is associated with a down-regulation of vascular endothelial growth factor expression in tumor cells. FASEB J. 16:2002;1802-1804.
25. Hanai J., Dhanabal M., Karumanchi S.A., Albanese C., Waterman M., Chan B., Ramchandran R., Pestell R., Sukhatme V.P. Endostatin causes G1 arrest of endothelial cells through inhibition of cyclin D1. J. Biol. Chem. 277:2002;16464-16469.
26. Hara E., Yamaguchi T., Nojima H., Ide T., Campisi J., Okayama H., Oda K. Id-related genes encoding helix-loop-helix proteins are required for G1 progression and are repressed in senescent human fibroblasts. J. Biol. Chem. 269:1994;2139-2145.
27. Haralabopoulos G.C., Grant D.S., Kleinman H.K., Maragoudakis M.E. Thrombin promotes endothelial cell alignment in Matrigel in vitro and angiogenesis in vivo. Am. J. Physiol. 273:1997;C239-C245.
28. Harris A.L. Hypoxia-a key regulatory factor in tumour growth. Nat. Rev. Cancer. 2:2002;38-47.
29. Hattori R., Hamilton K.K., Fugate R.D., McEver R.P., Sims P.J. Stimulated secretion of endothelial von Willebrand factor is accompanied by rapid redistribution to the cell surface of the intracellular granule membrane protein GMP-140. J. Biol. Chem. 264:1989;7768-7771.
30. Hebbar M., Peyrat J.P., Hornez L., Hatron P.Y., Hachulla E., Devulder B. Increased concentrations of the circulating angiogenesis inhibitor endostatin in patients with systemic sclerosis. Arthritis Rheum. 43:2000;889-893.
31. Hellwig-Burgel T., Rutkowski K., Metzen E., Fandrey J., Jelkmann W. Interleukin-1beta and tumor necrosis factor-alpha stimulate DNA binding of hypoxia-inducible factor-1. Blood. 94:1999;1561-1567.
32. Hughes P.E., Pfaff M. Integrin affinity modulation. Trends Cell Biol. 8:1998;359-364.
33. Iwasaka C., Tanaka K., Abe M., Sato Y. Ets-1 regulates angiogenesis by inducing the expression of urokinase- type plasminogen activator and matrix metalloproteinase-1 and the migration of vascular endothelial cells. J. Cell. Physiol. 169:1996;522-531.
34. Jeremias I., Kupatt C., Baumann B., Herr I., Wirth T., Debatin K.M. Inhibition of nuclear factor kappaB activation attenuates apoptosis resistance in lymphoid cells. Blood. 91:1998;4624-4631.
35. Karumanchi S.A., Jha V., Ramchandran R., Karihaloo A., Tsiokas L., Chan B., Dhanabal M., Hanai J.I., Venkataraman G., Shriver Z.et al. Cell surface glypicans are low-affinity endostatin receptors. Mol. Cell. 7:2001;811-822.
36. Kim Y.M., Jang J.W., Lee O.H., Yeon J., Choi E.Y., Kim K.W., Lee S.T., Kwon Y.G. Endostatin inhibits endothelial and tumor cellular invasion by blocking the activation and catalytic activity of matrix metalloproteinase. Cancer Res. 60:2000;5410-5413.
37. Kim Y.M., Hwang S., Kim Y.M., Pyun B.J., Kim T.Y., Lee S.T., Gho Y.S., Kwon Y.G. Endostatin blocks vascular endothelial growth factor-mediated signaling via direct interaction with KDR/Flk-1. J. Biol. Chem. 277:2002;27872-27879.
38. Kovary K., Bravo R. The jun and fos protein families are both required for cell cycle progression in fibroblasts. Mol. Cell. Biol. 11:1991;4466-4472.
39. Kraemer M., Tournaire R., Dejong V., Montreau N., Briane D., Derbin C., Binetruy B. Rat embryo fibroblasts transformed by c-Jun display highly metastatic and angiogenic activities in vivo and deregulate gene expression of both angiogenic and antiangiogenic factors. Cell Growth Differ. 10:1999;193-200.
40. Kucharz E.J., Gozdzik J., Kopec M., Kotulska A., Lewicki M., Pieczyrak R., Widuchowska M., Zakliczynska H., Szarzynska-Ruda M., Zycinska-Debska E. A single infusion of infliximab increases the serum endostatin level in patients with rheumatoid arthritis. Clin. Exp. Rheumatol. 21:2003;273-274.
41. Lennon G., Auffray C., Polymeropoulos M., Soares M.B. The I.M.A.G.E. Consortium. an integrated molecular analysis of genomes and their expression Genomics. 33:1996;151-152.
42. Lin C.Q., Singh J., Murata K., Itahana Y., Parrinello S., Liang S.H., Gillett C.E., Campisi J., Desprez P.Y. A role for Id-1 in the aggressive phenotype and steroid hormone response of human breast cancer cells. Cancer Res. 60:2000;1332-1340.
43. Lyden D., Hattori K., Dias S., Costa C., Blaikie P., Butros L., Chadburn A., Heissig B., Marks W., Witte L.et al. Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nat. Med. 7:2001;1194-1201.
44. Lyden D., Young A.Z., Zagzag D., Yan W., Gerald W., O'Reilly R., Bader B.L., Hynes R.O., Zhuang Y., Manova K.et al. Id1 and Id3 are required for neurogenesis, angiogenesis and vascularization of tumour xenografts. Nature. 401:1999;670-677.
45. Ma L., del Soldato P., Wallace J.L. Divergent effects of new cyclooxygenase inhibitors on gastric ulcer healing. Shifting the angiogenic balance Proc. Natl. Acad. Sci. USA. 99:2002;13243-13247.
46. McBride J.L., Ruiz J.C. Ephrin-A1 is expressed at sites of vascular development in the mouse. Mech. Dev. 77:1998;201-204.
47. Nakano T., Abe M., Tanaka K., Shineha R., Satomi S., Sato Y. Angiogenesis inhibition by transdominant mutant Ets-1. J. Cell. Physiol. 184:2000;255-262.
48. Oda N., Abe M., Sato Y. ETS-1 converts endothelial cells to the angiogenic phenotype by inducing the expression of matrix metalloproteinases and integrin beta3. J. Cell. Physiol. 178:1999;121-132.
49. O'Reilly M.S., Boehm T., Shing Y., Fukai N., Vasios G., Lane W.S., Flynn E., Birkhead J.R., Olsen B.R., Folkman J. Endostatin. an endogenous inhibitor of angiogenesis and tumor growth Cell. 88:1997;277-285.
50. Pandey A., Shao H., Marks R.M., Polverini P.J., Dixit V.M. Role of B61, the ligand for the Eck receptor tyrosine kinase, in TNF-alpha-induced angiogenesis. Science. 268:1995;567-569.
51. Papapetropoulos A., Piccardoni P., Cirino G., Bucci M., Sorrentino R., Cicala C., Johnson K., Zachariou V., Sessa W.C., Altieri D.C. Hypotension and inflammatory cytokine gene expression triggered by factor Xa-nitric oxide signaling. Proc. Natl. Acad. Sci. USA. 95:1998;4738-4742.
52. Ramchandran R., Karumanchi S.A., Hanai J., Alper S.L., Sukhatme V.P. Cellular actions and signaling by endostatin. Crit. Rev. Eukaryot. Gene Expr. 12:2002;175-191.
53. Rao L.V., Pendurthi U.R. Factor VIIIa-induced gene expression. potential implications in pathophysiology Trends Cardiovasc. Med. 11:2001;14-21.
54. Riewald M., Kravchenko V.V., Petrovan R.J., O'Brien P.J., Brass L.F., Ulevitch R.J., Ruf W. Gene induction by coagulation factor Xa is mediated by activation of protease-activated receptor 1. Blood. 97:2001;3109-3116.
55. Rousseau S., Houle F., Landry J., Huot J. p38 MAP kinase activation by vascular endothelial growth factor mediates actin reorganization and cell migration in human endothelial cells. Oncogene. 15:1997;2169-2177.
56. Seidel J.J., Graves B.J. An ERK2 docking site in the Pointed domain distinguishes a subset of ETS transcription factors. Genes Dev. 16:2002;127-137.
57. Semenza G.L. HIF-1 and tumor progression. pathophysiology and therapeutics Trends Mol. Med. 8:2002;S62-S67.
58. Sharrocks A.D. The ETS-domain transcription factor family. Nat. Rev. Mol. Cell Biol. 2:2001;827-837.
59. Shaulian E., Karin M. AP-1 as a regulator of cell life and death. Nat. Cell Biol. 4:2002;E131-E136.
60. Shichiri M., Hirata Y. Antiangiogenesis signals by endostatin. FASEB J. 15:2001;1044-1053.
61. Shin E.Y., Kim S.Y., Kim E.G. c-Jun N-terminal kinase is involved in motility of endothelial cell. Exp. Mol. Med. 33:2001;276-283.
62. Shirai K., Okada Y., Saika S., Senba E., Ohnishi Y. Expression of transcription factor AP-1 in rat lens epithelial cells during wound repair. Exp. Eye Res. 73:2001;461-468.
63. Shono T., Ono M., Izumi H., Jimi S.I., Matsushima K., Okamoto T., Kohno K., Kuwano M. Involvement of the transcription factor NF-kappaB in tubular morphogenesis of human microvascular endothelial cells by oxidative stress. Mol. Cell. Biol. 16:1996;4231-4239.
64. Siegbahn A. Cellular consequences upon factor VIIa binding to tissue factor. Haemostasis. 30(Suppl 2):2000;41-47.
65. Sovak M.A., Bellas R.E., Kim D.W., Zanieski G.J., Rogers A.E., Traish A.M., Sonenshein G.E. Aberrant nuclear factor-kappaB/Rel expression and the pathogenesis of breast cancer. J. Clin. Invest. 100:1997;2952-2960.
66. Sudhakar A., Sugimoto H., Yang C., Lively J., Zeisberg M., Kalluri R. Human tumstatin and human endostatin exhibit distinct antiangiogenic activities mediated by alpha v beta 3 and alpha 5 beta 1 integrins. Proc. Natl. Acad. Sci. USA. 100:2003;4766-4771.
67. Trikha M., Zhou Z., Timar J., Raso E., Kennel M., Emmell E., Nakada M.T. Multiple roles for platelet GPIIb/IIIa and alphavbeta3 integrins in tumor growth, angiogenesis, and metastasis. Cancer Res. 62:2002;2824-2833.
68. Tsopanoglou N.E., Maragoudakis M.E. On the mechanism of thrombin-induced angiogenesis. Potentiation of vascular endothelial growth factor activity on endothelial cells by up-regulation of its receptors. J. Biol. Chem. 274:1999;23969-23976.
69. Volpert O.V., Pili R., Sikder H.A., Nelius T., Zaichuk T., Morris C., Shiflett C.B., Devlin M.K., Conant K., Alani R.M. Id1 regulates angiogenesis through transcriptional repression of thrombospondin-1. Cancer Cell. 2:2002;473-483.
70. Wang C.Y., Mayo M.W., Baldwin A.S. Jr. TNF- and cancer therapy-induced apoptosis. potentiation by inhibition of NF-kappaB Science. 274:1996;784-787.
71. Wang H.U., Chen Z.F., Anderson D.J. Molecular distinction and angiogenic interaction between embryonic arteries and veins revealed by ephrin-B2 and its receptor Eph-B4. Cell. 93:1998;741-753.
72. Watnick R.S., Cheng Y.-N., Rangarajan A., Ince T.A., Weinberg R.A. Ras modulates Myc activity to repress thrombospondin-1 expression and increase tumor angiogenesis. Cancer Cell. 3:2003;219-231.
73. Yang B.S., Hauser C.A., Henkel G., Colman M.S., Van Beveren C., Stacey K.J., Hume D.A., Maki R.A., Ostrowski M.C. Ras-mediated phosphorylation of a conserved threonine residue enhances the transactivation activities of c-Ets1 and c-Ets2. Mol. Cell. Biol. 16:1996;538-547.
74. Yin G., Liu W., An P., Li P., Ding I., Planelles V., Schwarz E.M., Min W. Endostatin gene transfer inhibits joint angiogenesis and pannus formation in inflammatory arthritis. Mol. Ther. 5:2002;547-554.
75. Zucker S., Mirza H., Conner C.E., Lorenz A.F., Drews M.H., Bahou W.F., Jesty J. Vascular endothelial growth factor induces tissue factor and matrix metalloproteinase production in endothelial cells. conversion of prothrombin to thrombin results in progelatinase A activation and cell proliferation Int. J. Cancer. 75:1998;780-786.